Case Reports: Synthetic Cannabinoid Improves Outcomes in Patients with Chronic Gastrointestinal Disorders

Modena, Italy: The administration of nabilone, a FDA-approved synthetic CB1-receptor agonist, is associated with improved health in patients with chronic gastrointestinal (GI) disorders, according to a case series published in the journal BMC Gastroenterology.

Italian researchers assessed the use of naboline over a three-month period in six patients with severe GI disorders. They reported, "[O]ral nabilone improved the health of nearly all patients, with visible improvements in reducing diarrheal symptoms and weight gain. … Moreover, even though the duration of the therapy did not exceed three months, improvements were maintained over time."

Authors concluded, "To the best of our knowledge, this is the first study that provide preliminary evidence that a CB1-receptor agonist may be safe and play a beneficial role when the outcomes are focused on chronic GI disorders, especially on the diarrheal symptom."

For more information, contact Paul Armentano, NORML Deputy Director. Full text of the study, "Nabilone administration in refractory chronic diarrhea: A case series," appears in BMC Gastroenterology.